Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Pilot Study Reports Beneficial Effects Of Ambroxol For Fibromyalgia Pain

Saturday 20 May 2017


From Fibromyalgia News Today:



Pilot Study Reports Beneficial Effects of Ambroxol for Fibromyalgia Pain

By Alice Melão
Monday May 8, 2017

Results from a pilot clinical study published in the journal Clinical Rheumatology showed that ambroxol may help manage pain in fibromyalgia patients.

Ambroxol is mainly known as a mucolytic and expectorant agent. It has been used for decades in the treatment of various airway disorders, helping to restore the normal clearance mechanisms of the respiratory tract.

Previous studies have shown that ambroxol has the capacity to block the response of sodium channels, which are responsible for the transmission of pain sensations caused by nerve damage or dysfunction (neuropathic pain). The drug was shown to be 13 times more potent compared to other known calcium channel blockers, such as benzocaine, Xylocaine (lidocaine), and Mexitil (mexiletine).

It’s been previously suggested that fibromyalgia could have a neuropathic nature. Indeed, a study performed by researchers from Mexico found that some patients with fibromyalgia presented a mutation on a sodium channel gene associated with neuropathic pain signals. These findings support the hypothesis that sodium channel blocker agents might have a therapeutic potential for this medical condition.

The authors of the study, “Ambroxol for fibromyalgia: one group pretest-posttest open-label pilot study,” tried to identify the add-on benefits of ambroxol to standard fibromyalgia treatment regimens.


Full article…


Arrow right

More Fibromyalgia News



blog comments powered by Disqus
Previous Previous Page